Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK SLE-1: Phase 3 Study of Deucravacitinib in Active Systemic Lupus Erythematosus
CTR20230595Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deucravacitinib in systemic lupus erythematosus (SLE), sponsored by Bristol Myers Squibb. Started Aug 2023; status: active.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20230595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230595.